Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | ABL1 |
Variant | F359C |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | ABL1 F359C lies within the protein kinase domain of the Abl1 protein (UniProt.org). F359C has been identified as a secondary drug resistance mutation in the context of BCR-ABL1 (PMID: 19798095, PMID: 26773037), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Oct 2022). |
Associated Drug Resistance | Y |
Category Variants Paths |
ABL1 mutant ABL1 F359C |
Transcript | NM_005157.5 |
gDNA | chr9:g.130873028T>G |
cDNA | c.1076T>G |
Protein | p.F359C |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_005157 | chr9:g.130873028T>G | c.1076T>G | p.F359C | RefSeq | GRCh38/hg38 |
NM_005157.5 | chr9:g.130873028T>G | c.1076T>G | p.F359C | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04793399 | Phase Ib/II | Atezolizumab + Bosutinib | Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients | Recruiting | ESP | 0 |
NCT04160546 | Phase II | Aspirin + Ponatinib | Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP) | Recruiting | ESP | 0 |
NCT03874858 | Phase II | Nilotinib | A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia Treated With Nilotinib (DANTE) | Recruiting | ITA | 0 |